Explore the vast range of titles available.

PurposeEndocrine therapy (ET) used to reduce the risk of recurrence in hormone receptor-expressing disease (75% of breast cancers) is associated with worsening of climacteric symptoms with a negative impact on quality of life (QoL). Homeopathy might allow a better management of hot flushes (HF).MethodsIn this multicenter randomized double-blind placebo-controlled phase III study (ClinicalTrials.gov NCT01246427), we enrolled ≥ 18 years old women with histologically proven non metastatic localized breast cancer, with Eastern Cooperative Oncology Group-Performance Status (ECOG-PS) ≤ 1, treated for at least 1 month with adjuvant ET, and complaining about moderate to severe HF. Patients should not be scheduled for chemotherapy or radiotherapy, and had no associated pathology known to induce HF. After a 2- to 4-week placebo administration, we randomly assigned (1:1) patients with HFS ≥ 10 using an interactive web-based centralized platform to BRN-01 homeopathic medicine complex (Actheane®) in arm A or Placebo (Arm P). Randomization was stratified by adjuvant ET (taxoxifen/aromatase inhibitor) and recruiting site. HF scores (HFS) were calculated as the mean of HF frequencies before randomization, at 4, and at 8 weeks post-randomization (pre-, 4w,- and 8w-) weighted by a 4-level intensity scale. Primary endpoint was assessed at 4-week post-randomization, as the variation between pre- and 4w-HFS. Secondary endpoints included HFS variation between pre- and 8w-HFS, compliance and tolerance assessed 8 weeks after randomization, and QoL and satisfaction assessed at 4- and 8-week post-randomization.ResultsTwo hundred ninety-nine patients were included, and 138 (46.2%) randomized (A, 65; P, 73). Median 4w-HFS absolute variation (A, − 2.9; P, − 2.5 points, p = 0.756) and relative decrease (A, − 17%; P, − 15%, p = 0.629) were not statistically different. However, 4w-HFS decreased for 46 (75%) in A vs 48 (68%) patients in P arm. 4w-QoL was stable or improved for respectively 43 (72%) vs 51 (74%) patients (p = 0.470).ConclusionsThe efficacy endpoint was not reached, and BRN-01 administration was not demonstrated as an efficient treatment to alleviate HF symptoms due to adjuvant ET in breast cancer patients. However, the study drug administration led to decreased HFS with a positive impact on QoL. Without any recommended treatment to treat or alleviate the HF-related disabling symptoms, Actheane® could be a promising option, providing an interesting support for better adherence to ET, thereby reducing the risk of recurrence with a good tolerance profile.

This study aimed to obtain a microbial active compound as a novel antimalarial drug from Indonesian isolates. Target-based assays were used to screen for antimalarial activity against the parasite mitochondrial, Plasmodium falciparum malate:quinone oxidoreductase (PfMQO) enzyme. In total, 1600 crude extracts, composed from 800 fungi and 800 actinomycetes extracts, were screened against PfMQO, yielding six active extracts as primary hits. After several stages of stability tests, one extract produced by Aspergillus sp. BioMCC f.T.8501 demonstrated stable PfMQO inhibitory activity. Several purification stages, including OCC, TLC, and HPLC, were performed to obtain bioactive compounds from this active extract. All purification steps were followed by an assay against PfMQO. We identified the active compound as nornidulin based on its LC-MS and UV spectrum data. Nornidulin inhibited PfMQO activity at IC50 of 51 µM and P. falciparum 3D7 proliferation in vitro at IC50 of 44.6 µM, however, it had no effect on the growth of several mammalian cells. In conclusion, we isolated nornidulin from Indonesian Aspergillus sp. BioMCC f.T.8501 as a novel inhibitor of PfMQO, which showed inhibitory activity against the proliferation of P. falciparum 3D7 in vitro.

\"Trusted naturopath Dr. JJ Pursell shares 375 herbal recipes that support the daily health and wellness of every member of the household\"-- Provided by publisher.

Ancient classic and famous prescriptions (ACFPs), derived from traditional Chinese medicine (TCM) classics, are widely utilized due to their precise therapeutic effects and distinctive clinical advantages. Existing research predominantly focuses on individual prescriptions, and there is lack of systematic exploration of medication patterns within the official ACFPs catalog. The property of Chinese materia medica (PCMM), a multidimensional representation of medicinal properties, offers a novel perspective for systematically analyzing TCM formulas. In this study, we aim to investigate the implicit medication patterns of ACFPs from the PCMM perspective, establish a feature extraction model based on the property combination of Chinese materia medica (PCCMM), and evaluate its effectiveness in representing and reconstructing ACFPs. Based on the Chinese Pharmacopoeia (ChP), we constructed a CMM-PCCMM network as the forward feature extraction process. We formulated the backward process as a constrained combinatorial optimization problem to rebuild ACFPs from their PCCMMs. We evaluated the performance of PCCMM in reconstructing ACFPs using the Jaccard similarity coefficient. Furthermore, we tested the capability of PCCMM to distinguish ACFPs from random pseudo-formulas and classify ACFPs according to deficiency syndromes. Finally, we conducted frequency analysis, association rule analysis, distance analysis, and correlation analysis to explore the implicit medication patterns of ACFPs based on PCCMM. Numerical experiments showed that PCCMM effectively represented and reconstructed ACFPs, achieving an average Jaccard similarity coefficient above 0.8. PCCMM outperformed the nomenclature of CMM in distinguishing ACFPs from random pseudo-formulas and classifying deficiency syndromes. Frequency analysis revealed that high-frequency CMMs were mainly tonic medicines, whereas high-frequency PCCMMs predominantly mapped to the even-sweet-spleen meridian. The association rule analysis based on PCCMM yielded significantly more implicit compatibility rules than CMM alone. Distance and correlation analyses identified synergistic CMM pairs and PCCMM pairs, such as (Dazao) and (Shengjiang), which is consistent with clinical experience. The PCCMM-based feature extraction model provides a quasi-equivalent representation of TCM formulas, effectively capturing implicit medication patterns within ACFPs. PCCMM outperforms traditional CMM methods in formula reconstruction, classification, and medication pattern mining. This study offers novel insights and methodologies for systematically understanding TCM formulas, guiding clinical application, and facilitating the design and optimization of new TCM formulas.

Although there are many texts that provide quality information for the identification of fungi, researchers and technologists rarely have time to read the text. Most are rushed for time and seek morphological information that helps guide them to the identification of fungi. The Atlas of Clinically Important Fungi provides readers with an alphabetical list of fungi as well as listing the division of fungi by both sporulation and morphology. The characteristic traits for a particular fungus are displayed through a series of images, with the fungi appearing as they did in the author's lab on the day(s) that testing was performed. For this reason, numerous (6-20) color photographs are included so that technologists will have sufficient reference photos for identifying the various morphologies of a single organism. Organism photographs begin with the macroscopic colony views followed by the microscopic views. Also included for some microorganisms, are clinical pathology photographs demonstrating how the organism appears in human tissues. A collection of literature citations are also provided to enable further reading. This user-friendly fungi atlas provides a resource for those seeking information in the field of medical mycology, specifically with regards to identifying an organism using the parameters of culture morphology.

\"Dig into the world of herbal medicine with this complete guide to cultivating and harvesting plants with healing properties. For thousands of years, people have been utilizing herbs and cultivating weeds found to speed the healing of wounds, soothe skin irritations, calm uneasy stomachs, and ward off illnesses. In these pages, you'll learn the basics of gardening in your backyard or on your windowsill or porch. You'll also find profiles of useful herbs that are easy to grow or wildcraft, along with inspiring stories, medicine-making instructions, and recipes for your home medicine chest. Known to boost immunity, reduce blood pressure, aid digestion, and relieve arthritis among other medicinal properties, powerful plants such as garlic, Echinacea, yarrow, elderflower, mint, elecampane, and many more are included in this illustrated guide.\"--provided by publisher.

Objectives To investigate the effectiveness and safety of homeopathic medicine Natrum muriaticum (LM2) for mild cases of COVID-19 in Primary Health Care. Trial design A randomized, two-armed (1:1), parallel, placebo-controlled, double-blind, clinical trial is being performed to test the following hypotheses: H0: homeopathic medicines = placebo (null hypothesis) vs. H1: homeopathic medicines ≠ placebo (alternative hypothesis) for mild cases of COVID-19 in Primary Care. Participants Setting: Primary Care of São Carlos – São Paulo – Brazil. One hundred participants aged 18 years or older, with Influenza-like symptoms and a positive RT-PCR for SARS-CoV-2. Willingness to give informed consent and to comply with the study procedures is also required. Exclusion criterium: severe acute respiratory syndrome. Intervention and comparator Homeopathy: 1 globule of Natrum muriaticum LM2 diluted in 20 mL of alcohol 30% and dispensed in a 30 ml bottle. Placebo: 20 mL of alcohol 30% dispensed in a 30 ml bottle. Posology: one drop taken orally every 4 hours (6 doses/day) while there is fever, cough, tiredness, or pain (headache, sore throat, muscle aches, chest pain, etc.) followed by one drop every 6 hours (4 doses/day) until the fourteenth day of use. The bottle of study medication should be submitted to 10 vigorous shakes (succussions) before each dose. Posology may be changed by telemedicine, with no break in blinding. Study medication should be maintained during home isolation. According to the Primary Care protocol, the home isolation period lasts until the 10 th day after the appearance of the first symptom, or up to 72 hours without symptoms. Main outcomes The primary endpoint will be time to recovery, defined as the number of days elapsed before all COVID-19 Influenza-like symptoms are recorded as mild or absent during home isolation period. Secondary measures are recovery time for each COVID-19 symptom; score of the scale created for the study (COVID-Simile Scale); medicines used during follow-up; number of days of follow-up; number of visits to emergency services; number of hospitalizations; other symptoms and Adverse Events during home isolation period. Randomisation The study Statistician generated a block randomization list, using a 1:1 ratio of the two groups (denoted as A and B) and a web-based tool ( http://www.random.org/lists ). Blinding (masking) The clinical investigators, the statistician, the Primary Care teams, the study collaborators, and the participants will remain blinded from the identity of the two treatment groups until the end of the study. Numbers to be randomised (sample size) One hundred participants are planned to be randomized (1:1) to placebo (50) or homeopathy (50). Trial Status Protocol version/date May 21, 2020. Recruitment is ongoing. First participant was recruited/included on June 29,2020. Due to recruitment adaptations to Primary Care changes, the authors anticipate the trial will finish recruiting on April 10, 2021. Trial registration COVID-Simile Study was registered at the University Hospital Medical Information Network (UMIN - https://www.umin.ac.jp/ctr/index.htm ) on June 1 st , 2020, and the trial start date was June 15, 2020. Unique ID: UMIN000040602. Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1 ). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.